Vertex Pharmaceuticals Given New $125.00 Price Target at Leerink Swann (VRTX)
Equities researchers at Leerink Swann upped their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $100.00 to $125.00 in a research report issued on Wednesday. The firm currently has an “outperform” rating on the stock. Leerink Swann’s price target indicates a potential upside of 33.65% from the stock’s previous close.
Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 93.53 on Wednesday. Vertex Pharmaceuticals has a one year low of $58.06 and a one year high of $98.80. The stock’s 50-day moving average is $69.89 and its 200-day moving average is $73.39. The company’s market cap is $22.091 billion. Vertex Pharmaceuticals also was the target of unusually large options trading on Monday. Stock investors acquired 13,082 call options on the company. This represents an increase of 235% compared to the average daily volume of 3,903 call options.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Thursday, May 1st. The company reported ($0.65) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter last year, the company posted $0.03 earnings per share. Vertex Pharmaceuticals’s revenue was down 63.9% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals will post $-2.82 EPS for the current fiscal year.
In other Vertex Pharmaceuticals news, EVP Peter Mueller sold 7,500 shares of Vertex Pharmaceuticals stock on the open market in a transaction dated Monday, June 16th. The shares were sold at an average price of $68.31, for a total transaction of $512,325.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at HC Wainwright downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday. They now have a $85.00 price target on the stock, down previously from $105.00. Separately, analysts at Needham & Company LLC raised their price target on shares of Vertex Pharmaceuticals from $95.00 to $115.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Vertex Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $95.44.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.